28 March 2022 - Evusheld retains neutralising activity against the Omicron BA.2 subvariant, now the dominant strain in Europe
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union for the pre-exposure prophylaxis of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.